SENS.L Regulatory News (SENS)

Notice of Interim Results

Oxford, UK; 15 January 2019: Sensyne Health plc (LSE: SENS) (the "Company"), the British clinical AI technology company, will announce its Interim Results for the 6 months ended 31 October 2018, on Monday 28 January 2019.

Lord Drayson, Chief Executive Officer, and Lorimer Headley, Chief Financial Officer, will host a briefing for analysts at 10.30am on the morning of the results at 85 Gresham Street, London, EC2R 7HE.

A live webcast of the meeting, with the presentation slides, will be available via the Company website.

-ENDS-

For more information please contact:

About Sensyne Health

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care's 'Initial Code of Conduct for data-driven health and care technology'.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information, please visit: www.sensynehealth.com